ADA guidelines recommended sodium–glucose cotransporter 2 (SGLT-2) inhibitor or glucagon-like peptide 1 (GLP-1) receptor agonist for T2DM patients who have established ASCVD or have indicators of high-risk, established kidney disease, or HF, with demonstrated CVD benefit is recommended as part of the glucose-lowering regimen independent of A1C and in consideration of patient-specific factors (19, 41). This evidence concerns the gene SLC5A2 and kidney disorder.